Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3313883 | 1.00 | NPC1 (0.33) | NPC1RAB9ASMN1; SMN2HSD17B10CYP2C9 | |
| SCHEMBL17141150 | 0.87 | NPC1 (0.34) | NPC1RAB9ASMN1; SMN2HSD17B10GRM4 | |
| SCHEMBL3319508 | 0.87 | NPC1 (0.34) | NPC1RAB9ASMN1; SMN2HSD17B10GRM4 | |
| SCHEMBL3319502 | 0.87 | NPC1 (0.34) | NPC1RAB9ASMN1; SMN2HSD17B10GRM4 | |
| SCHEMBL3311973 | 0.85 | GRM4 (0.33) | GRM4 | |
| SCHEMBL3311979 | 0.85 | GRM4 (0.33) | GRM4 | |
| SCHEMBL16116237 | 0.84 | ALDH1A1 (0.38) | NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL3316889 | 0.84 | THRA (0.34) | NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL3319831 | 0.84 | ALDH1A1 (0.38) | NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL3319836 | 0.84 | ALDH1A1 (0.38) | NPC1RAB9ASMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3577116-B1 | DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO[1,2-A]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS | CHANGZHOU QIANHONG BIO PHARMA CO LTD (CN) | 2025-04-23 | — | — | EP | disclosed |
| US-20240425476-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2024-12-26 | — | — | US | disclosed |
| CN-114269742-B | Derivatives of 4- (imidazo [1,2-a ] pyridin-3-yl) -N- (pyridinyl) pyrimidin-2-amine as therapeutic agents | 常州千红生化制药股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240182441-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2024-06-06 | — | — | US | disclosed |
| EP-4119551-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | Astrazeneca AB (SE) | 2023-01-18 | — | — | EP | disclosed |
| US-11524951-B2 | 2-(2,4,5-substituted-anilino)pyrimidine compounds | ASTRAZENECA AB (SE) | 2022-12-13 | — | — | US | disclosed |
| EP-4086246-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS AS EGFR MODULATORS | AstraZeneca AB (SE) | 2022-11-09 | — | — | EP | disclosed |
| CN-114269742-A | Derivatives of 4- (imidazo [1,2-a ] pyridin-3-yl) -N- (pyridinyl) pyrimidin-2-amines as therapeutic agents | 常州千红生化制药股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-110418789-B | Derivatives of N-cycloalkyl/heterocycloalkyl-4- (imidazo [1,2-a ] pyridine) pyrimidin-2-amines as therapeutic agents | 常州千红生化制药股份有限公司 | 2022-03-25 | — | — | CN | disclosed |
| US-11111245-B2 | Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2021-09-07 | — | — | US | disclosed |
| US-9732058-B2 | 2-(2,4,5-substituted-anilino)pyrimidine compounds | ASTRAZENECA AB (SE) | 2017-08-15 | — | — | US | disclosed |
| EP-3009431-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER | Astrazeneca AB (SE) | 2016-04-20 | — | — | EP | disclosed |
| EP-2736895-B1 | 2-(2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2016-01-06 | — | — | EP | disclosed |
| US-20150119379-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2015-04-30 | — | — | US | disclosed |
| US-8946235-B2 | 2-(2,4,5-substituted-anilino) pyrimidine compounds | ASTRAZENECA AB (SE) | 2015-02-03 | — | — | US | disclosed |
| EP-2736895-A1 | 2 - (2, 4, 5 - SUBSTITUTED -ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER | Astrazeneca AB (SE) | 2014-06-04 | — | — | EP | disclosed |
| US-20130053409-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2013-02-28 | — | — | US | disclosed |
| WO-2013014448-A1 | 2 - (2, 4, 5 - SUBSTITUTED -ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2013-01-31 | — | — | WO | disclosed |
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053409-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE COMPOUNDS | EGFR, ERBB2, ERBB3 | NPC1 1895/4885RAB9A 250/4885SMN1; SMN2 2671/4885 |
| US-20240425476-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | EGFR, ERBB2, ERBB3 | NPC1 1895/4885RAB9A 250/4885SMN1; SMN2 2671/4885 |
| US-20150119379-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | EGFR, ERBB2, ERBB3 | NPC1 1895/4885RAB9A 250/4885SMN1; SMN2 2671/4885 |
| US-11524951-B2 | 2-(2,4,5-substituted-anilino)pyrimidine compounds | EGFR, ERBB2, ERBB3 | NPC1 1895/4885RAB9A 250/4885SMN1; SMN2 2671/4885 |
| US-11111245-B2 | Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents | CDK2, CDKL1, CDKL2 | NPC1 4511/4885RAB9A 3617/4885SMN1; SMN2 2867/4885 |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | NPC1 279/4885RAB9A 943/4885SMN1; SMN2 1509/4885 |
| US-20240182441-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | EGFR, ERBB2, ERBB3 | NPC1 1895/4885RAB9A 250/4885SMN1; SMN2 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.